Edgar Filing: Ophthotech Corp. - Form 4

Ophthotech Form 4 May 03, 20	•										
FORM /								OMB APPROVAL			
	UNITED	Washington, D.C. 20549							3235-0287		
Check the check	ger								January 31, 2005		
subject Section Form 4	16.	LENT OF (CHANGES I SEC	EKSHIP OF	Estimated a burden hou response	•					
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type	Responses)										
PATEL SAMIR CHANDRAKANT Symbol				and Ticke		8	5. Relationship of Reporting Person(s) to Issuer				
(Last) (First) (Middle)			Ophthotech Corp. [OPHT]				(Check all applicable)				
(Last)	(11151) (14		Month/Day/Yea	of Earliest Transaction /Day/Year)X				_X Director 10% Owner			
C/O OPHTHOTECH 04/29/2 CORPORATION, ONE PENN PLAZA, 19TH FLOOR				2016				below)	Other (specify)		
(Street) 4. If Ame				endment, Date Original			6. Individual or Joint/Group Filing(Check				
Filed(Mo NEW YORK, NY 10119				Year)			Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)	Table I - No	on-Derivat	ive Secu		ired, Disposed of,	or Beneficial	ly Owned		
1.Title of Security (Instr. 3)		ansaction Date 2A. Deemed th/Day/Year) Execution Date, if any (Month/Day/Year)			3. 4. Securities Acquired (A Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			6.7. Nature ofOwnershipIndirectForm:BeneficialDirect (D)Ownershipor Indirect(Instr. 4)(I)(Instr. 4)			
			Code	V Amo			(Instr. 3 and 4)				
Common Stock	04/29/2016		M <u>(1)</u>	1,41	3 A	\$ 1.652	231,008	D			
Common Stock	04/29/2016		M <u>(1)</u>	1,184	4 A	\$ 13.216	232,192	D			
Common Stock	04/29/2016		S <u>(1)</u>	18,43	35 D	\$ 46.71 (2)	213,757	D			
Common Stock	04/29/2016		S <u>(1)</u>	1,56	5 D	\$ 47.78 (<u>3)</u>	212,192	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number prof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	of Derivative Expiration Date Securities (Month/Day/Ye Acquired (A) or Disposed of (D) (Instr. 3, 4,		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. l De Sec (In
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right To Buy)	\$ 1.652	04/29/2016		M <u>(1)</u>	1,413	<u>(4)</u>	04/08/2022	Common Stock	1,413	
Stock Option (Right To Buy)	\$ 13.216	04/29/2016		M <u>(1)</u>	1,184	(5)	05/28/2023	Common Stock	1,184	

Reporting Owners

Reporting Owner Name / Address	Relationships					
F	Director	10% Owner	Officer	Other		
PATEL SAMIR CHANDRAKANT C/O OPHTHOTECH CORPORATION ONE PENN PLAZA, 19TH FLOOR NEW YORK, NY 10119	Х		President			
Signatures						
/s/ Justin Vogel, as Attorney-in-Fact for Patel	05/03/2016					
**Signature of Reporting Person		D	Date			

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1)

Edgar Filing: Ophthotech Corp. - Form 4

The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2015.

These shares were disposed of in multiple transactions on April 29, 2016 at actual sales prices ranging from \$46.16 to \$47.15 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request

(2) The precipient reflects the weighted average sale precipient of the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

These shares were disposed of in multiple transactions on April 29, 2016 at actual sales prices ranging from \$47.24 to \$48.05 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request

- (3) The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (4) This option was granted on April 9, 2012 and is currently exercisable for all shares underlying the option.
- (5) This option was granted on May 29, 2013 and vests over four years, with 2.0833% of the original number of shares underlying the option vesting monthly from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.